THE SINGLE BEST STRATEGY TO USE FOR LP-PLA2-IN-1

Contraindicated (one)bortezomib will improve the amount or outcome of mavacamten by affecting hepatic enzyme CYP2C19 metabolism. Contraindicated. Powerful or moderate CYP2C19 inhibitors might boost mavacamten systemic exposure, causing heart failure as a consequence of systolic dysfunction.Acute enhancement or exacerbation of congestive coronary he